share_log

Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $52

Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $52

坎托·菲茨杰拉德维持对Celldex Therapeutics的增持,将目标股价下调至52美元
Benzinga ·  2023/11/03 12:49

Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $54 to $52.

坎托·菲茨杰拉德分析师克里斯汀·克鲁斯卡维持Celldex Therapeutics(纳斯达克股票代码:CLDX)增持 “增持”,并将目标股价从54美元下调至52美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发